Wednesday, September 22, 2004

Pharmacists' Diabetes Services in Australia: "Objective: To implement and evaluate a specialized service for type 2 diabetes mellitus in the community pharmacy."
Advances in Diabetes for the Millennium: Insulin Treatment and Glucose Monitoring: "Newer insulins and easier blood glucose monitoring have greatly improved the ability to obtain excellent control of blood glucose levels with less risk of hypoglycemia. In type 1 diabetes, insulin pump therapy remains the optimal approach with the most flexibility, especially with the ultra-fast-acting analogs lispro or aspart. Otherwise, once- or twice-daily dosing with the long-acting analog glargine provides excellent basal coverage, and lispro or aspart at meals provides bolus coverage, all in the attempt to mimic physiological insulin secretion. For type 2 diabetes, although oral agents continue to be a mainstay of therapy, it is clear that many patients require insulin to attain the goal A1c of < 6.5%. Once-daily glargine is now used more commonly after 1-2 oral agents have failed, and it typically takes the place of sulfonylureas. The future will likely have better systems for continuous glucose monitoring and novel therapies to control glucose through agents that affect gut hormones."
Diabetics Exposed to Telmisartan and Enalapril
: "The first long-term study to compare an angiotensin receptor blocker (ARB) and an angiotensin-converting enzyme (ACE) inhibitor in patients with hypertension and early-stage type 2 diabetic nephropathy has shown that the ARB telmisartan and the ACE inhibitor enalapril have comparable long-term renoprotective effects.[1] The Diabetics Exposed to Telmisartan And Enalapril (DETAIL) trial is thus the first to show that an ARB offers renoprotection that is clinically equivalent to that of an ACE inhibitor."

Wednesday, September 15, 2004

: "There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose."
Red Meat Increases Type 2 Diabetes Risk in Older Women: "NEW YORK (Reuters Health) Sept 09 - Middle age and elderly women with high levels of red meat in their diet appear to have an increased risk of developing type 2 diabetes, according to a study published in the September issue of Diabetes Care"